Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population

JAMA

Volumn 290, Issue 2, 2003, Pages 228-237

  Salomon, Joshua A ^a,b,c   Weinstein, Milton C ^c   Hammitt, James K ^c   Goldie, Sue J ^c  

^a HARVARD CENTER FOR POPULATION AND DEVELOPMENT STUDIES   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c HARVARD CENTER FOR RISK ANALYSIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A;

ADULT; AGED; ARTICLE; CALIBRATION; CHRONIC HEPATITIS; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; POPULATION RISK; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE DIAGNOSIS; RNA ANALYSIS; SERODIAGNOSIS; SURVIVAL; UNITED STATES; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COST; ECONOMICS; HEALTH CARE COST; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIFE EXPECTANCY; LIVER CIRRHOSIS; MALE; MARKOV CHAINS; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; UNITED STATES;

EID: 0038352047     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.2.228     Document Type: Article

References (78)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
2. Tong MJ, el Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466.
3. US Department of Health and Human Services. Hepatitis C: an emerging threat to public health (HHS Fact Sheet). Washington, DC: US Dept of Health and Human Services, 2001.
4. Satcher D. Letter from the Surgeon General. Office of the Surgeon General (Rockville, MD). Available at: http://www.surgeongeneral.gov/topics/hepatitisc /letter.htm. Accessed October 6, 2001.
5. Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Morb Mortal Wkly Rep. 2003;52(RR-1):1-36.
6. Seeff LB. Natural history of hepatitis C. Am J Med. 1999;107:10S-15S.
7. Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol. 2002;17:423-430.
8. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection. Semin Liver Dis. 2000;20:17-35.
9. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492.
10. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(3 suppl 1): 112S-121S.
11. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38-47.
12. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002;36(5 suppl 1):S3-S20.
13. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically-calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002;156:761-773.
14. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology. 1995;22:1863-1873.
15. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-865.
16. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866-874.
17. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA. 1998;280:2088-2093.
18. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318-1324.
19. Wong JB. Cost-effectiveness of treatments for chronic hepatitis C. Am J Med. 1999;107:74S-78S.
20. Shiell A, Brown S, Farrell GC. Hepatitis C: an economic evaluation of extended treatment with interferon. Med J Aust. 1999;171:189-193.
21. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastoenterol. 2000;95:1524-1530.
22. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. Ann Intern Med. 2000;133:665-675.
23. Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med. 2000;108:366-373.
24. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol. 2000;33:651-658.
25. Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J. 2000;19:23-30.
26. Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2001;13:483-488.
27. Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol. 2001;36:870-876.
28. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut. 2002;50:253-258.
29. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterologica Belgica. 2002;65:110-111.
30. Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002;162:2545-2556.
31. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
32. Takahashi M, Yamada G, Miyamoto R, et al. Natural course of chronic hepatitis C. Am J Gastroenterol. 1993;88:240-243.
33. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-1340.
34. Roberts JM, Searle JW, Cooksley WG. Histological patterns of prolonged hepatitis C infection. Gastroenterologia Japonica. 1993;28(suppl 5):37-41.
35. Kiyosawa K, Tanaka E, Sodeyama T, Furuta S. Natural history of hepatitis C. Intervirology. 1994;37:101-107.
36. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission. Hepatology. 1993;18:1338-1343.
37. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C. Hepatology. 1998;28:1687-1695.
38. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis. Liver. 1993;13:274-278.
39. Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology. 2000;32:582-587.
40. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-456.
41. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med. 1993;119:110-115.
42. Hopf U, Moller B, Kuther D, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol. 1990;10:69-76.
43. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis. J Hepatol. 1992;16:273-281.
44. Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 1991;14:969-974.
45. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis. Hepatology. 2001;33:455-463.
46. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology. 2000;32:91-96.
47. Kenny-Walsh E, Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228-1233.
48. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105-111.
49. Poynard T, Bedossa P, Opolon P, the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825-832.
50. Matsumura H, Moriyama M, Goto I, et al. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment. J Viral Hepat. 2000;7:268-275.
51. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1 pt 1):15-20.
52. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-524.
53. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology. 1999;116:378-386.
54. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut. 1993;34(2 suppl): S13-S16.
55. Fattovich G, Glustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C. Gastroenterology. 1997;112:463-472.
56. Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites. Am J Gastroenterol. 1993;88:514-519.
57. Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices. Hepatology. 1994;20:618-625.
58. Christensen E, Krintel JJ, Hansen SM, Johansen JK, Juhl E. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Scand J Gastroenterol. 1989;24:999-1006.
59. Poynard T, Marcellin P, Lee SS, et al, International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
60. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet. 2001;358:958-965.
61. Barbaro G, Di Lorenzo G, Soldini M, et al, Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. J Hepatol. 2000;33:448-455.
62. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
63. Camma C, Di M, V, Lo IO, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol. 1998;28:531-537.
64. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875-881.
65. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 1995;21:918-922.
66. Lau DT, Kleiner DE, Ghany MG, et al. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28:1121-1127.
67. Okanoue T, Itoh Y, Minami M, et al, Viral Hepatitis Therapy Study Group. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage. J Hepatol. 1999;30:653-659.
68. Yoshida H, Shiratori Y, Moriyama M, et al, IHIT Study Group: Inhibition of Hepatocarcinogenesis by Interferon Therapy. Interferon therapy reduces the risk for hepatocellular carcinoma. Ann Intern Med. 1999;131:174-181.
69. Drug Topics Red Book. Montvale, NJ: Medical Economics; 2001.
70. Zaman A, Goldberg RJ, Pettit KG, et al. Cost of treating an episode of variceal bleeding in a VA setting. Am J Gastroenterol. 2000;95:1323-1330.
71. Russo MW, Zacks SL, Sandler RS, Brown RS. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology. 2000;31:358-363.
72. Wong LL, McFall P, Wong LM. The cost of dying of end-stage liver disease. Arch Intern Med. 1997;157:1429-1432.
73. Cotler SJ, Patil R, McNutt RA, et al. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. Am J Gastroenterol. 2001;96:2730-2736.
74. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(4 pt 1):809-816.
75. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36(5 suppl 1):S210-S219.
76. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002;36(5 suppl 1):S201-S209.
77. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study. Med Decis Making. 1993;13:89-102.
78. Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making. 1997;17:483-489.